CAR-T therapy is a specialized autologous technology whereby a patient’s own T-cells are transfected with an engineered chimeric antigen receptor (CAR) and then re-introduced to the body to fight cancer. The technology, first described in 1989, enables a CAR-T lymphocyte to have antigen specificity to a variety of targets e.g. including proteins, carbohydrates and glycolipids but also incorporates a
T-cell signaling mechanism to allow for T-cell activation and a cytotoxic response. CAR-T cell immunotherapy has recently been named “Advance of the Year” in the Annual ASCO report, 2017.
CD19 targeted CAR-T therapies such as Novartis’ Kymriah(TM) (tisagenlecleucel) and Gilead/Kite’s Yescarta(TM) (axicabtagene ciloleucel) were both first FDA approved in 2017 for relapsing/recurring forms of pediatric acute lymphoblastic lymphoma (B-ALL) and Diffuse Large B-cell lymphoma (DLBCL), a common type of non-Hodgkin lymphoma (NHL), respectively. Further submissions in the EU and Rest of World regions are either submitted or planned for 2018 and beyond. The emergence of new CAR-T cell therapies as a market segment has so far driven considerable company acquisitive activity (Gilead/Kite, Celgene/ Juno Therapeutics)
and with further technologies (BCMA) and target indications (MM, CLL, FL) planned, we expect substantial market development over the next few years.
This MarketVIEW forecast summary product consists of a detailed Executive presentation (~55 slides, .pdf) which summarizes the commercial potential ($ 000s) of novel CAR-T therapies in r/r B-ALL, NHL (DLBCL) and CLL across 9 major Western markets to 2030 in all relevant age groups. The summary outputs are derived from models* which incorporate a proprietary patient-based flow methodology which include possible intervention scenarios for CAR-T introduction. In this summary slide deck, graphical/tabular outputs of these models are provided with all main assumptions.
An Executive Summary for each indication is also included.
THIS PRODUCT IS A SUMMARY PRESENTATION (.pdf, 55 slides)
*full model workbooks are provided in seperate products